at CNBC.com (Sep 25, 2014)
There are no Focus articles on IMCL.
There are no Transcripts on IMCL.
We currently have no Breaking News on this stock.
There are no StockTalks on this stock yet.
IMCL vs. ETF Alternatives
ImmunoClin concentrates its innovation on developing personalized, preventive strategies to fight inflammatory conditions that are the underlying cause of pathologies in multiple conditions affecting the majority of human population: infections, cancer, cardiovascular disease, and dementia,... More
Other News & PR